Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2026-01-22 Regulatory Filings
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Rekomendowanie projektu Ryvu do dofinansowania przez Narodowe Centrum Badań i Rozwoju / Recommendation of Ryvu's project for funding by the National Centre for Research and Development - Content (EN)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from Ryvu Therapeutics S.A. regarding the selection of a company project for government funding by the National Centre for Research and Development (NCBR). It details the project scope, financial value, and funding amount. Since it is a specific corporate announcement regarding a business development/financing event that does not fit into the other specialized categories like M&A, dividends, or share issues, it falls under the general regulatory announcement category.
2026-01-22 English
Rekomendowanie projektu Ryvu do dofinansowania przez Narodowe Centrum Badań i Rozwoju / Recommendation of Ryvu's project for funding by the National Centre for Research and Development - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a current report issued by Ryvu Therapeutics S.A. regarding the selection of their project for funding by the National Centre for Research and Development (NCBR). It describes a specific corporate event (grant funding) rather than a financial report, proxy, or governance document. Since it is a regulatory announcement of a material corporate development that does not fit into specific categories like M&A or share issues, it is classified as a general regulatory filing.
2026-01-22 Polish
Aktualizacja dotycząca spotkania Typu C z amerykańską Agencją Żywności i Leków (FDA) w sprawie romacyklibu (RVU120) / Update on Food and Drug Administration (FDA) Type C meeting regarding romacicli...
Legal Proceedings Report Classification · 1% confidence The document is an official announcement from Ryvu Therapeutics regarding the outcome of a regulatory meeting with the U.S. Food and Drug Administration (FDA) concerning a clinical trial program. It details the feedback received, the company's next steps, and regulatory compliance actions. As it pertains to specific regulatory interactions and clinical development updates that do not fit into financial reporting or corporate governance categories, it is best classified as a Regulatory Filing (RNS).
2026-01-19 English
Aktualizacja dotycząca spotkania Typu C z amerykańską Agencją Żywności i Leków (FDA) w sprawie romacyklibu (RVU120) / Update on Food and Drug Administration (FDA) Type C meeting regarding romacicli...
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement from Ryvu Therapeutics S.A. regarding the outcome of a 'Type C' meeting with the U.S. FDA concerning the clinical development of their drug candidate, romacyklib (RVU120). It details the FDA's feedback, the company's clinical trial strategy, and future regulatory steps. Since this is a specific update on regulatory interactions and clinical trial progress that does not fit into financial reporting, dividend announcements, or board changes, it is best classified as a general regulatory filing.
2026-01-19 Polish
Notyfikacja CapitalS Fundacja Rodzinna w organizacji
Major Shareholding Notification Classification · 1% confidence The document is a formal notification ('Zawiadomienie') regarding a change in shareholding structure, specifically referencing Article 69 of the Polish Act on Public Offering. It details the acquisition of shares by 'CAPITALS FUNDACJA RODZINNA W ORGANIZACJI' in 'RYVU THERAPEUTICS SPÓŁKA AKCYJNA', resulting in the entity crossing a significant shareholding threshold (5.06% of votes). This is a classic Major Shareholding Notification.
2025-12-31 Polish
Notyfikacja Bogusław Sieczkowski
Major Shareholding Notification Classification · 1% confidence The document is a formal notification ('Zawiadomienie') submitted under Article 69 of the Polish Act on Public Offering. It details a change in shareholding structure by a major shareholder (Bogusław Sieczkowski) in the company Ryvu Therapeutics S.A. due to a donation of shares. This is a standard regulatory disclosure regarding significant share ownership thresholds, which falls under the 'Major Shareholding Notification' category.
2025-12-31 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.